- Home
- CEE vs UNCY Comparison
CEE vs UNCY Comparison
Compare CEE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- UNCY
- Stock Information
- Founded
- CEE 1990
- UNCY 2016
- Country
- CEE Germany
- UNCY United States
- Employees
- CEE N/A
- UNCY N/A
- Industry
- CEE Finance Companies
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- UNCY Health Care
- Exchange
- CEE Nasdaq
- UNCY Nasdaq
- Market Cap
- CEE 99.9M
- UNCY 91.0M
- IPO Year
- CEE N/A
- UNCY 2021
- Fundamental
- Price
- CEE $15.85
- UNCY $4.87
- Analyst Decision
- CEE
- UNCY Strong Buy
- Analyst Count
- CEE 0
- UNCY 4
- Target Price
- CEE N/A
- UNCY $63.75
- AVG Volume (30 Days)
- CEE 22.0K
- UNCY 934.5K
- Earning Date
- CEE 01-01-0001
- UNCY 08-13-2025
- Dividend Yield
- CEE 3.86%
- UNCY N/A
- EPS Growth
- CEE N/A
- UNCY N/A
- EPS
- CEE N/A
- UNCY N/A
- Revenue
- CEE N/A
- UNCY N/A
- Revenue This Year
- CEE N/A
- UNCY N/A
- Revenue Next Year
- CEE N/A
- UNCY $1,458.53
- P/E Ratio
- CEE N/A
- UNCY N/A
- Revenue Growth
- CEE N/A
- UNCY N/A
- 52 Week Low
- CEE $7.80
- UNCY $2.02
- 52 Week High
- CEE $10.32
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- CEE 59.73
- UNCY 45.55
- Support Level
- CEE $15.00
- UNCY $4.38
- Resistance Level
- CEE $15.98
- UNCY $4.96
- Average True Range (ATR)
- CEE 0.39
- UNCY 0.31
- MACD
- CEE 0.03
- UNCY 0.05
- Stochastic Oscillator
- CEE 92.49
- UNCY 41.88
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.